Faeth Therapeutics (FTH) Total Debt (2020 - 2021)

Faeth Therapeutics' (FTH) quarterly Total Debt came in at $567000.0 in Q2 2021, little changed on a QoQ basis from $567000.0 in Q1 2021.

Faeth Therapeutics (FTH) Total Debt (2020 - 2021) Analysis & Trends

Faeth Therapeutics (FTH) has 2 years of Total Debt data on file, last reported at $567000.0 in Q2 2021.

Quarterly Total Debt changed N/A year-over-year to $567000.0 in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $567000.0 (changed N/A YoY) and the FY2020 annual result came in at $567000.0, changed N/A from the prior year.
Total Debt steadied at $567000.0 in Q2 2021, from $567000.0 in the prior quarter.
In the past five years, Total Debt ranged from a high of $567000.0 in Q4 2020 to a low of $567000.0 in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Vertex Pharmaceuticals	139.90 Bn	132.05 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.70 Bn	78.71 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	65.73 Bn	60.55 Bn	1.37 Bn	-
4	Moderna	58.33 Bn	53.19 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	42.16 Bn	37.07 Bn	1.53 Bn	1.07 Bn
6	Alnylam Pharmaceuticals	31.72 Bn	28.42 Bn	992.69 Mn	-
7	BioNTech SE	28.27 Bn	9.88 Bn	668.28 Mn	770.36 Mn
8	Insmed	27.61 Bn	26.45 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.25 Bn	26.41 Bn	-	9.34 Bn
10	Faeth Therapeutics	179.40 Mn	179.40 Mn	-	-

Download Data